MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Tokai Pharmaceuticals Company Profile (NASDAQ:TKAI)

Consensus Ratings for Tokai Pharmaceuticals (NASDAQ:TKAI) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.25 (237.13% upside)

Analysts' Ratings History for Tokai Pharmaceuticals (NASDAQ:TKAI)
Show:
DateFirmActionRatingPrice TargetActions
4/12/2016Janney Montgomery ScottReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016Bank of America Corp.Initiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Oppenheimer Holdings Inc.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Wells Fargo & Co.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2014Jefferies GroupInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2014William BlairInitiated CoverageOutperform$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2014Stifel NicolausInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Tokai Pharmaceuticals (NASDAQ:TKAI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/10/2016Q1($0.50)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.47)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.50)($0.40)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.31)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015($0.40)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.42)($2.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Tokai Pharmaceuticals (NASDAQ:TKAI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.56)($0.56)($0.56)
Q2 20161($0.63)($0.63)($0.63)
Q3 20161($0.68)($0.68)($0.68)
Q4 20161($0.73)($0.73)($0.73)
(Data provided by Zacks Investment Research)
Dividend History for Tokai Pharmaceuticals (NASDAQ:TKAI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Tokai Pharmaceuticals (NASDAQ:TKAI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/15/2016Stephen Jr. BuckleyDirectorBuy8,000$5.74$45,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Stephen Jr. BuckleyDirectorBuy3,000$11.25$33,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015John S. McbrideCOOSell13,500$14.01$189,135.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Lee KalowskiCFOSell4,668$13.13$61,290.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Lee KalowskiCFOSell2,158$12.96$27,967.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Bioventures Ltd NovartisMajor ShareholderSell3,566$14.26$50,851.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015Bioventures Ltd NovartisMajor ShareholderSell27,861$14.41$401,477.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Bioventures Ltd NovartisMajor ShareholderSell20,611$14.20$292,676.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Jodie Pope MorrisonCEOSell16,000$13.77$220,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2015John S McbrideCOOSell9,000$14.01$126,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015John S McbrideCOOSell6,700$14.00$93,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015John S McbrideCOOSell2,000$14.02$28,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Bioventures Ltd NovartisMajor ShareholderSell1,120$14.27$15,982.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Bioventures Ltd NovartisMajor ShareholderSell27,875$14.20$395,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2015Lee KalowskiCFOSell4,567$13.00$59,371.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Lee KalowskiCFOSell2,258$11.45$25,854.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Bioventures Ltd NovartisMajor ShareholderSell49,141$14.50$712,544.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Apple Tree Partners Ii - AnnexDirectorBuy237,500$15.00$3,562,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Tokai Pharmaceuticals (NASDAQ:TKAI)
DateHeadline
06/24/16 09:22 AMTokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 09:22 AMTokai Pharmaceuticals, Inc. (TKAI) Current Analyst Ratings - Fiscal Standard
06/22/16 06:45 PMTokai Pharmaceuticals, Inc. (NasdaqGM:TKAI) Stock Momentum Hits Weakness - CML News
06/21/16 06:18 PMThis Weeks Broker Views For Tokai Pharmaceuticals, Inc. (TKAI) - Fiscal Standard
06/16/16 06:02 AMTOKAI PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/06/16 01:30 PMTokai Pharmaceuticals, Inc. :TKAI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/05/16 09:31 AMTokai Pharmaceuticals Incorporated (NASDAQ:TKAI) Short Interest Decreased By 1.04% - HNN
06/03/16 07:31 PMStock Review and Earnings Check on Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) - HNN
06/02/16 07:19 PMTokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Stock Update & Estimates - Stock Tick Tock - Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) to post earnings of $-0.54 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/02/16 10:02 AMInsiders Are Gradually Buying Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) - HNN - Insiders Are Gradually Buying Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI)HNNAccording to the latest SEC filings, insiders at Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) have increased their position in the stock by 13.30% over the past 6 months. Insiders now own 0.30% of total outstanding shares. There are both legal and illegal ...
06/02/16 06:15 AMTokai Pharmaceuticals to Participate in Upcoming Investor Conferences - [at noodls] - BOSTON--(BUSINESS WIRE)--Jun. 2, 2016-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other ...
06/01/16 07:32 PMTarget Price and Stock Performance Rundown for Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) - HNN - Target Price and Stock Performance Rundown for Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI)HNNDuring the latest trading session, Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) shares traded -1.36%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
05/31/16 06:13 AMTOKAI PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -
05/30/16 01:20 PMTokai Pharmaceuticals, Inc. (TKAI) Broker Price Targets For The Coming Week - Share Trading News - Tokai Pharmaceuticals, Inc. (TKAI) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Tokai Pharmaceuticals, Inc. (TKAI). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...Tokai Pharmaceuticals Incorporated (NASDAQ:TKAI) Shorts Decreased by 1.04% After Short CoveringThe Postall 3 news articles »
05/26/16 11:30 AMInsiders Are Gradually Buying Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) - Wall Street Hints and News - Insiders Are Gradually Buying Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) have increased their position in the stock by 13.45% over the past 6 months. Insiders now own 0.30% of total outstanding shares. There are both legal and illegal ...and more »
05/26/16 11:30 AMTokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Impact Score At 0 - Investor Newswire - Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Impact Score At 0Investor NewswireAlpha One explored various online articles released on Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), and it set a daily sentiment score of -0.39 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the ...and more »
05/18/16 06:27 PMTokai Announces Publication of Three Abstracts on Galeterone at the 2016 ASCO Annual Meeting - [Business Wire] - Tokai Pharmaceuticals Inc. , a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that data related to galeterone will be presented in two posters at the 2016 American Society of Clinical Oncology Annual Meeting, which will take place from June 3-7, 2016, in Chicago.
05/10/16 06:49 AMTokai Pharmaceuticals reports 1Q loss -
05/10/16 06:38 AMTokai Pharmaceuticals Reports First Quarter 2016 Financial Results - [at noodls] - BOSTON--(BUSINESS WIRE)--May 10, 2016-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other ...
05/10/16 06:11 AMTOKAI PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/09/16 07:50 AMShould You Buy Tokai Pharmaceuticals (TKAI) Ahead of Earnings? -
05/05/16 08:51 AMTokai Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference - [at noodls] - BOSTON--(BUSINESS WIRE)--May 5, 2016-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other ...
04/26/16 06:16 AMTokai Announces Oral Presentation on Galeterone at the 2016 AUA Annual Meeting - [at noodls] - BOSTON--(BUSINESS WIRE)--Apr. 26, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other ...
04/13/16 06:12 AMTokai Announces Presentations on Galeterone at the AACR Annual Meeting 2016 - [at noodls] - BOSTON--(BUSINESS WIRE)--Apr. 13, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other ...
03/10/16 07:19 AMTokai Pharmaceuticals reports 4Q loss -
03/10/16 07:00 AMTokai Pharmaceuticals Reports Full Year 2015 Financial Results - [Business Wire] - Tokai Pharmaceuticals Inc. , a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the year ended December 31, 2015.
03/10/16 06:18 AMTOKAI PHARMACEUTICALS INC Files SEC form 10-K, Annual Report -
02/26/16 10:38 AMTokai Pharmaceuticals, Inc. (TKAI) Analyst Updates - Risers & Fallers - Tokai Pharmaceuticals, Inc. (TKAI) Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Tokai Pharmaceuticals, Inc. (TKAI). According to the latest broker reports outstanding on Wednesday 24th of February, 5 analysts have a rating of “strong buy”, 0 ...Tokai Pharmaceuticals Inc (TKAI) Downgraded by Zacks Investment Research to "Sell"The Hilltop Newsall 2 news articles »
02/26/16 10:38 AMTokai Pharmaceuticals, Inc. (TKAI) New Analyst Ratings - Share Trading News - Tokai Pharmaceuticals, Inc. (TKAI) New Analyst RatingsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Tokai Pharmaceuticals, Inc. (TKAI). The latest reports which are currently in issue on Friday 26th of February state 5 analysts have a rating of “strong buy”, 0 analysts ...Tokai Pharmaceuticals Incorporated (NASDAQ:TKAI) Short Interest Decreased By 1.89%SmallCapWired.comall 2 news articles »
02/15/16 01:16 PMCan Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Move Higher On Charts? - Stocks Daily - Intercooler FinancialCan Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Move Higher On Charts?Stocks DailyThe research group Zacks released a report as per which Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) shares can hit a high of $38 in the forthcoming fiscal. Zacks included several brokerages in the poll and thereafter defined a price target of $31.333 on ...FY2015 Earnings Forecast for Tokai Pharmaceuticals Inc Issued By Oppenheimer (TKAI)Intercooler Financialall 3 news articles »
02/03/16 09:20 PMTokai Pharmaceuticals, Inc. (TKAI) - Tokai Announces Presentation of Galeterone Data in Models of the AR-V7 Splice Variant at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire (Sat, Nov 7)
02/01/16 12:10 PMCompany Shares of Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Rally 3.98% - Bull Report - Company Shares of Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Rally 3.98%Bull ReportShares of Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) appreciated by 3.98% during the past week but lost 28.1% on a 4-week basis. The shares have outperformed the S&P 500 by 2.19% in the past week but underperformed the index by 24.25% in the last 4 ...
01/29/16 12:12 PMRecent Broker Updates On Tokai Pharmaceuticals, Inc. (TKAI) - Risers & Fallers - Recent Broker Updates On Tokai Pharmaceuticals, Inc. (TKAI)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Tokai Pharmaceuticals, Inc. (TKAI). The latest broker reports which are currently outstanding on Friday 29th January state 5 analysts have a rating of “strong buy”, 0 ...and more »
01/27/16 06:45 PMTokai Pharmaceuticals, Inc. (NASDAQ:TKAI): Quarterly Earnings Update - Investor Newswire - Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI): Quarterly Earnings UpdateInvestor NewswireAs per the brokerage research firms surveyed by Zacks Research, Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) is expected to post earnings per share of $-0.21 for last fiscal quarter. The company can announce the results on or around 2016-03-10. Since the ...and more »
01/25/16 11:34 AMCompany Shares of Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Rally 13.13% - WallStreet Prudent - Company Shares of Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Rally 13.13%WallStreet PrudentShares of Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) appreciated by 13.13% during the past week but lost 33% on a 4-week basis. The shares have outperformed the S&P 500 by 11.56% in the past week but underperformed the index by 27.59% in the last ...
01/22/16 06:24 PMWhy Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Stock Is In The Spotlight? - Stocks Daily - Why Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Stock Is In The Spotlight?Stocks DailyTokai Pharmaceuticals, Inc. (NASDAQ:TKAI) have been getting positive report from the sell-side analysts. Zacks published the results of recently conducted poll wherein the company cherished a mean rating of 1 rating. To make it clearer, this number is ...and more »
01/20/16 11:17 AMTokai Pharmaceuticals, Inc. (NASDAQ:TKAI) - Stock Sentiment And ABR Update - Investor Newswire - Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) - Stock Sentiment And ABR UpdateInvestor NewswireZacks Research has given an average broker rating of 1 to Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI)'s shares. Zacks assigns a simplified score in between one and five against the complex analysts' ratings. A score towards 1-2 typically means a ...and more »
01/19/16 10:54 AMPrice Target Update On Tokai Pharmaceuticals, Inc. (TKAI) - Risers & Fallers - Price Target Update On Tokai Pharmaceuticals, Inc. (TKAI)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Tokai Pharmaceuticals, Inc. (TKAI). According to the latest broker reports 5 analysts have a rating of “buy”, 0 analysts “outperform”, 0 analysts “hold”, 0 analysts ...and more »
01/17/16 05:59 PMTokai Pharmaceuticals, Inc. (NASDAQ:TKAI): Stock in the spotlight - Stocks Daily - Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI): Stock in the spotlightStocks DailySell-side analysts maintain a positive outlook on the shares of Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI). Based on the poll results published by the Zacks Research, the stock of the company has been assigned a 1 rating. This number represents the ...Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) Stock Target and Ratings UpdateSmallCapWired.comall 4 news articles »
01/08/16 02:36 PMTokai Announces Presentation of New Data Highlighting Unique Galeterone Mechanism at ASCO Genitourinary Cancers Symposium - [at noodls] - --(BUSINESS WIRE)--Jan. 8, 2016-- (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today ...
01/07/16 06:32 AMTOKAI PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi -
01/07/16 06:11 AMTokai Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program - [at noodls] - Top-line Data for ARMOR3-SV Expected by Mid-2017 for First Half of 2016 --(BUSINESS WIRE)--Jan. 7, 2016-- (NASDAQ: TKAI) today provided an update on its clinical development program evaluating galeterone ...
12/21/15 07:45 AMTokai Pharmaceuticals (TKAI): Strong Industry, Solid Earnings Estimate Revisions -
12/08/15 12:17 PMTOKAI PHARMACEUTICALS INC Financials -
12/02/15 06:16 AMTokai Pharmaceuticals to Present at the Oppenheimer 26th Annual Healthcare Conference - [at noodls] - BOSTON--(BUSINESS WIRE)--Dec. 2, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other ...
11/30/15 03:01 AMDo Hedge Funds Love Tokai Pharmaceuticals Inc (TKAI)? -
11/10/15 07:07 AMTokai Pharmaceuticals reports 3Q loss -
About Tokai Pharmaceuticals

Tokai Pharmaceuticals logoTokai Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company's lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation. The Company develops galeterone for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC. The Company is conducting a pivotal Phase III clinical trial comparing galeterone to Xtandi (enzalutamide) in approximately 148 treatment-naive mCRPC patients whose prostate tumors express the AR-V7 splice variant. The Company refers clinical trial as ARMOR3-SV, a precision-medicine based pivotal clinical trial in prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TKAI
  • CUSIP:
Key Metrics:
  • Previous Close: $5.71
  • 50 Day Moving Average: $6.54
  • 200 Day Moving Average: $6.71
  • P/E Ratio: N/A
  • P/E Growth: 0.04
  • Market Cap: $127.12M
  • Current Quarter EPS Consensus Estimate: $-2.00 EPS
Additional Links:
Tokai Pharmaceuticals (NASDAQ:TKAI) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha